TrialBritish journal of cancer2019

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.

Nicoletta Colombo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.